Dual-Oriented Targeted Nanostructured SERS Label-Free Immunosensor for Detection, Quantification, and Analysis of Breast Cancer Biomarker Concentrations in Blood Serum.

Mohammad E Khosroshahi, Christine Gaoiran, Vithurshan Umashanker, Hayagreev Veeru, Pranav Panday

Abstract read

In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad E KhosroshahiNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.ORCID 0000-0002-6628-5569

Christine GaoiranNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.

Vithurshan UmashankerNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.ORCID 0009-0002-6205-4816

Hayagreev VeeruNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.

Pranav PandayNanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON L4B 1B4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical applications of surface-enhanced Raman spectroscopy (SERS) immunosensors, accurately determining analyte biomarker concentrations is essential. This study presents a non-invasive approach for quantifying various breast cancer biomarkers-including human epidermal growth factor receptor II (HER-II) (2+, 3+ (I), 3+ (II), 3+ (III), and positive IV) and CA 15-3-using a directional, plasmonically active, label-free SERS sensor. Each stage of sensor functionalization, conjugation, and biomarker interaction was verified by UV-Vis spectroscopy. Atomic force microscopy (AFM) characterized the morphology of gold nanourchin (GNU)-immobilized printed circuit board (PCB) substrates. An enhancement factor of ≈ 0.5 × 10

Indexed as

Biomarkers, TumorBiosensing TechniquesBreast NeoplasmsSpectrum Analysis, RamanFemaleGoldHumansImmunoassayNanostructuresBiomarkers, TumorGoldbreast cancer biomarkersconcentration quantificationdirectional antibodygold nanourchinsurface-enhanced Raman scattering

Identifiers

PMID40710097

DOI10.3390/bios15070447

PMCPMC12293741

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.